A-M. Spiroski, M. H. Oliver, J. E. Harding and F. H. Bloomfield Pages 168 - 178 ( 11 )
Fetal growth restriction (FGR) is associated with an increased incidence of fetal and neonatal death, and of neonatal morbidity. Babies born following FGR also are at risk of a range of postnatal complications, which may contribute to an increased incidence of disease later in life. There currently are no effective clinical interventions which improve perinatal survival, intrauterine growth and later outcomes of the FGR baby. Postnatal interventions aimed at promoting or accelerating growth in FGR babies to improve outcome, particularly neurodevelopmental outcomes, may further increase the risk of metabolic dysregulation and, therefore, the risk of developing chronic disease in adulthood. An intrauterine intervention to improve nutrition and growth in the FGR fetus may have the potential to decrease mortality and improve long-term outcomes by delaying preterm delivery and mitigating the need for and risks of accelerated postnatal growth.
Fetal therapies, growth and development, growth hormone, infant, insulin-like growth factor-I, placenta, preterm, developmental origins of health and disease.
Liggins Institute, University of Auckland, Private Bag 92019, Auckland, New Zealand.